Dr. Loggie’s Career Highlights
Highlights from Dr. Loggie’s inspiring career include:
- Pioneering heated chemotherapy treatments for peritoneal cancer
- Serving as director of the Cancer Center at Creighton University Medical Center
- Serving as director of the Mesothelioma Applied Research Foundation, developing new and improved treatments for mesothelioma
- Specializing in the treatment and management of rare complex cancers like mesothelioma
“When I started, we had very little treatment. I started an experimental protocol to operate on these patients [and] remove the tumors, [which] always came back after surgery if you didn’t do anything else.
So we added heated intraperitoneal chemotherapy as a profusion at the end of surgery, and we were kind of astonished by the results.”
—Dr. Brian Loggie
Dr. Loggie pioneered the use of heated chemotherapy, a technique that can manage or eliminate some complex forms of abdominal cancer, including peritoneal mesothelioma.
“Based on how patients did before that, we weren’t expecting to see very many 1-year survivors, [but we] started seeing 1-, and 2-, and 3-, and 5-year survivors,” he said.
Although Dr. Loggie is now retired, you can find other top mesothelioma specialists near you using our Free Doctor Match.
Dr. Loggie’s Background
Dr. Loggie earned his medical degree at McGill University in Montreal, Canada, before completing his internship and residency at the Montreal General Hospital.
While a resident, Dr. Loggie also earned a graduate degree from the Department of Experimental Surgery at McGill University. He then completed a Clinical and Research Fellowship in Surgical Oncology at the University of Illinois.
He continued to refine his knowledge and expertise throughout the years, completing several courses and programs, including:
- Specialist Certificate in General Surgery, Royal College of Physicians and Surgeons of Canada
- Certificate of Training in Surgical Oncology, University of Illinois School of Medicine
- General Surgery, American Board of Surgery
Dr. Loggie has held teaching positions at numerous institutes, including the University of Illinois at Chicago, Wake Forest University, and the University of Texas Southwestern Medical Center. He also served as a surgical professor at the Creighton University School of Medicine in Omaha, Nebraska.
While working at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, Dr. Loggie developed hyperthermic intraperitoneal chemotherapy (HIPEC), also called heated chemotherapy, which can successfully treat many late-stage abdominal cancers.
Learn more about chemotherapy options in our Free Mesothelioma Guide — packed with nearly 100 pages of comprehensive information on this cancer.
Medical Specializations
Throughout his multi-decade practice, Dr. Loggie focused on the treatment of rare and aggressive cancers including tumors and mesothelioma.
He was especially known for developing effective management and treatment plans for patients with late-stage cancer. Dr. Loggie also specialized in heated chemotherapy, a highly effective mesothelioma treatment procedure that he developed.
Dr. Loggie’s Career Accomplishments
Dr. Loggie is best known for his development of heated chemotherapy, a procedure that has been successful in treating peritoneal mesothelioma and late-stage abdominal cancers. Most patients met Dr. Loggie after receiving a grim prognosis from other medical facilities, and his heated chemotherapy was a lifesaver for many of them.
Dr. Loggie also provided treatment for patients with terminal cancers, sometimes adding five or more years to their life expectancy. Many of his patients’ overall health and wellness drastically improved under Dr. Loggie’s care, even if their cancer was not completely eliminated.
Dr. Loggie was a champion for patients with rare forms of cancer, drawing research and funding to areas of oncology that are often overlooked by the general population. The quality of life of his patients was a high priority for him.
Awards & Honors
Dr. Loggie’s awards and honors include:
- Best Doctors in America (peer selected)
- Castle Connoly’s America’s Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Dr. Harold J. Bonnstetter Endowed Chair in Preventive Medicine
- Magis Award from Creighton University
Professional Affiliations
Dr. Loggie is also a member of several professional societies and organizations, including:
- Director, Mesothelioma Applied Research Foundation
- Fellow, American College of Surgeons
- Fellow, Royal College of Surgeons of Canada
- Fellow, Society of Surgical Oncology
- Member, International Society for Regional Cancer Therapy
- Member, American Society of Clinical Oncology
- Member, Association for Academic Surgery
Notable Works by Dr. Loggie
Dr. Loggie has made massive contributions to the peritoneal mesothelioma treatment landscape. In 2001, Dr. Loggie published his results from a prospective trial that studied this new therapy to treat peritoneal mesothelioma.
The purpose of the trial was to test the effectiveness of using cytoreduction (tumor-debulking) surgery in combination with intraoperative intraperitoneal heated chemotherapy, a therapy now known as cytroreduction with HIPEC. Dr. Loggie conducted this treatment approach on multiple patients.
Following the cytoreductive surgery, which removed as much of the tumors as possible, Dr. Loggie administered heated chemotherapy drugs directly into patients’ abdominal cavities for two hours.
The vast majority of patients involved in this trial significantly improved their survival time. By the time Dr. Loggie published his results, one patient had already remained cancer-free for five years. Though novel at the time, this approach has become a standardized and highly effective treatment for patients with peritoneal mesothelioma.
Connect With Other Top Mesothelioma Specialists
We can help you connect with top mesothelioma doctors who provide life-extending treatment for patients around the country.
Use our Free Doctor Match or call us at (866) 608-8933 — our Patient Advocates are available 24/7 to help you begin your treatment journey.
